Considering the results for the COVID-19 group at 20–30 days after the onset of symptoms, PBMCs from this time point were chosen for in vitro cultivation with bLf to explore their effects on the subpopulations of NK, CD4+ T, and CD8+ T cells. This evidence concerns the gene CD4 and COVID-19.